gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CRSPHealthcareBiotechnology

CRISPR Therapeutics AG (CRSP)

$51.78+3.57%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$49.99▼ 19.33% in range
Nov 3, 2025Low $44.34 · High $61.97Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

CRISPR Therapeutics AG closed at $51.77 on Nov 4, up 3.57%, 16.5% below its 52-week closing high. Volume of 1.4M shares was 0.98× its 20-day average (close to normal).

Split-adjusted performance: -4.1% over one month, -6.0% over six months, -16.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $12.67M, up 1325.1% from a year earlier, with a net margin of -879.6%.

Short interest was 16.4M shares at the Oct 15 settlement, down 12.0% from the prior report (21.0% of float, 10.2 days to cover).

Market cap$5.01B96.7M shares
Revenue · quarter$12.7M+1325.1% YoY
Diluted EPS$-1.15—
P/E · TTM—P/S 198.9×
Net margin-879.6%Gross 100.0%
Dividend yieldNone
52-week range44.34 – 61.97−16.5% from high
Volume1.4M0.98× 20-day avg
Volatility · 60d53.6%Annualised
Short % of float21.0%10.2 days to cover
Net cash$1.69BCash $2.27B
Next earnings—Not scheduled
Split-adjusted performance
1W −4.3%1M −4.1%3M +0.3%6M −6.0%YTD −1.3%1Y −16.5%3Y +33.0%5Y −44.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum63
Revenue growth94
Net margin32
Value (low P/E)—
Size86

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short16.4M−12.0% vs prior
Days to cover10.2Settled Oct 15
% of float21.0%
Short vol. 10d55.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CRSPCRISPR Therapeutics AG$51.78+3.57%−6.0%+1325.1%−879.6%—$5.01B
SRRKScholar Rock Holding$46.09+4.80%−2.2%———$5.61BCompare
ADPTAdaptive Biotechnologies$26.71+3.53%+85.1%+21.5%−55.6%—$4.26BCompare
CGONCG Oncology$67.71+5.70%−0.4%—−6832.8%—$6.00BCompare
IMVTImmunovant$29.90+2.96%+4.3%———$6.18BCompare
KODKodiak Sciences$98.51−0.38%+114.7%———$6.19BCompare
RLAYRelay Therapeutics$18.03+3.38%+39.6%−48.3%−23916.3%—$3.95BCompare
IOVAIovance Biotherapeutics$8.70−1.47%+112.7%+65.7%−47.6%—$3.94BCompare
DNLIDenali Therapeutics$20.96+7.76%+2.7%—−3539.2%—$3.35BCompare

News about CRISPR Therapeutics AG

All news →
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketZacks Investment Research · 5d agoNeutralCRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowZacks Investment Research · Oct 23, 2026▼ NegativeInvestors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to KnowZacks Investment Research · Oct 23, 2026▼ NegativeWhere Will CRISPR Therapeutics Stock Be in 2030?The Motley Fool · Oct 18, 2026NeutralCathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.The Motley Fool · Oct 18, 2026▲ Positive

Quick answers

What does CRISPR Therapeutics AG do?
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA.
What is CRSP's market cap?
$5.01B, based on the Nov 4 close of $51.77.
Does CRISPR Therapeutics AG pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CRSP is sold short?
16.4M shares, 21.0% of float, as of Oct 15, 2026.
What sector is CRSP in?
Healthcare, in the Biotechnology industry.

About CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

HQ: Zug, 393 employeesListed Oct 19, 2016crisprtx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology